Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
Status:
Unknown status
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
Null hypothesis of the trial is that there is no difference between solifenacin and
oxybutynin with respect to efficacy, side effects, patient satisfaction and quality of life
measures in patients with overactive bladder.
Phase:
Phase 4
Details
Lead Sponsor:
Adana Numune Training and Research Hospital
Collaborators:
Akdeniz University Ankara University Baskent University Cukurova University Gaziosmanpasa University Inonu University Kahramanmaras Sutcu Imam University Kocaeli University University of Gaziantep